Prevalence and Prognostic Role of Resistant Hypertension in Chronic Kidney Disease Patients

被引:127
|
作者
De Nicola, Luca [1 ]
Gabbai, Francis B. [2 ,3 ]
Agarwal, Rajiv [4 ,5 ]
Chiodini, Paolo [6 ]
Borrelli, Silvio [1 ]
Bellizzi, Vincenzo [7 ]
Nappi, Felice [8 ]
Conte, Giuseppe [1 ]
Minutolo, Roberto [1 ]
机构
[1] Univ Naples 2, Dept Nephrol, I-80125 Naples, Italy
[2] Vet Adm San Diego Healthcare Syst, Dept Med, San Diego, CA USA
[3] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[4] Indiana Univ Sch Med, Dept Med, Div Nephrol, Indianapolis, IN 46202 USA
[5] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA
[6] Univ Naples 2, I-80125 Naples, Italy
[7] Salerno Hosp, Dept Nephrol, Salerno, Italy
[8] Nola Hosp, Dept Nephrol, Nola, Italy
基金
美国国家卫生研究院;
关键词
ambulatory blood pressure monitoring; chronic kidney disease; resistant hypertension; BLOOD-PRESSURE CONTROL; EUROPEAN-SOCIETY; PROTEINURIA; DYSFUNCTION; COMMITTEE; PEOPLE; TARGET;
D O I
10.1016/j.jacc.2012.12.061
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study sought to evaluate in chronic kidney disease (CKD) prevalence and prognosis of true resistant hypertension (RH) (i.e., confirmed by ambulatory blood pressure [ABP] monitoring). Background In CKD, uncontrolled hypertension is a major risk factor, but no study has properly investigated the role of RH. Methods We prospectively studied 436 hypertensive CKD patients under nephrology care. Four groups were constituted by combining 24-h ABP with diagnosis of RH (office blood pressure >= 130/80 mm Hg, despite adherence to >= 3 full-dose antihypertensive drugs including a diuretic agent or >= 4 drugs): control (ABP <125/75 mm Hg without RH); pseudoresistance (ABP <125/75 mm Hg with RH); sustained hypertension (ABP >= 125/75 mm Hg without RH); and true resistance (ABP >= 125/75 mm Hg with RH). Endpoints of survival analysis were renal (end-stage renal disease or death) and cardiovascular events (fatal and nonfatal cardiovascular event). Results Age was 65 +/- 14 years, men 58%, diabetes 36%, cardiovascular disease 30%, median proteinuria 0.24 (interquartile range 0.09 to 0.83) g/day, estimated glomerular filtration rate 43 +/- 20 ml/min/1.73 m(2), office blood pressure 146 +/- 19/82 +/- 12 mm Hg, and 24-h ABP 129 +/- 17/72 +/- 10 mm Hg. True resistant patients were 22.9%, and pseudoresistant patients were 7.1%, whereas patients with sustained hypertension were 42.9%, and control subjects were 27.1%. Over 57 months of follow-up, 109 cardiovascular events and 165 renal events occurred. Cardiovascular risk (hazard ratio [95% confidence interval]) was 1.24 (0.55 to 2.78) in pseudoresistance, 1.11 (0.67 to 1.84) in sustained hypertension, and 1.98 (1.14 to 3.43) in true resistance, compared with control subjects. Corresponding hazards for renal events were 1.18 (0.45 to 3.13), 2.14 (1.35 to 3.40), and 2.66 (1.62 to 4.37). Conclusions In CKD, pseudoresistance is not associated with an increased cardio-renal risk, and sustained hypertension predicts only renal outcome. True resistance is prevalent and identifies patients carrying the highest cardiovascular risk. (C) 2013 by the American College of Cardiology Foundation
引用
收藏
页码:2461 / 2467
页数:7
相关论文
共 50 条
  • [21] HYPERTENSION IN CHINESE PATIENTS WITH CHRONIC KIDNEY DISEASE: PREVALENCE, MANAGEMENT AND PHARMACOEPIDEMIOLOGY
    Zhang, W.
    Shi, W.
    Liu, Z.
    Gu, Y.
    Chen, Q.
    Yuan, W.
    Zhang, Y.
    Gong, L.
    Zhou, R.
    Li, M.
    Cheng, H.
    Liu, J.
    Cen, J.
    Huang, C.
    Ren, Y.
    Mao, P.
    Xing, C.
    Hong, F.
    Jiang, D.
    Wang, L.
    Xu, G.
    Liu, J.
    Chen, N.
    NEPHROLOGY, 2016, 21 : 214 - 215
  • [22] Resistant Hypertension in Chronic Kidney Disease (CKD): Prevalence, Treatment Particularities, and Research Agenda
    Panagiotis I. Georgianos
    Rajiv Agarwal
    Current Hypertension Reports, 2020, 22
  • [23] Resistant Hypertension in Chronic Kidney Disease (CKD): Prevalence, Treatment Particularities, and Research Agenda
    Georgianos, Panagiotis I.
    Agarwal, Rajiv
    CURRENT HYPERTENSION REPORTS, 2020, 22 (10)
  • [24] THE PREVALENCE OF HYPERHOMOCYSTEINEMIA IN CHRONIC KIDNEY DISEASE PATIENTS WITH HYPERTENSION: DOES HOMOCYSTEINE CAUSE HYPERTENSION?
    Karunawan, Niyata Hananta
    Pinzon, Rizaldy Taslim
    JOURNAL OF HYPERTENSION, 2019, 37 : E2 - E3
  • [25] Role of Sodium Restriction and Diuretic Therapy for "Resistant" Hypertension in Chronic Kidney Disease
    Sinnakirouchenan, Ramapriya
    Kotchen, Theodore A.
    SEMINARS IN NEPHROLOGY, 2014, 34 (05) : 514 - 519
  • [26] Prevalence and Prognostic Impact of Diastolic Dysfunction in Patients with Chronic Kidney Disease on Hemodialysis
    Barberato, Silvio H.
    Bucharles, Sergio G. E.
    Sousa, Admar M.
    Costantini, Costantino O.
    Costantini, Costantino R. F.
    Pecoits-Filho, Roberto
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2010, 94 (04) : 457 - 462
  • [27] Ambulatory Blood Pressure Monitoring in Patients With Chronic Kidney Disease and Resistant Hypertension
    Shafi, Salman
    Sarac, Erdal
    Huy Tran
    JOURNAL OF CLINICAL HYPERTENSION, 2012, 14 (09): : 611 - 617
  • [28] RESISTANT HYPERTENSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES MELLITUS - AN OBSERVATIONAL STUDY
    Munteanu, Mircea
    Timar, Bogdan
    Timar, Romulus
    Sturza, Adrian
    Enache, Adrian
    Schiller, Adalbert
    INTERDIAB 2016: DIABETES MELLITUS AS CARDIOVASCULAR DISEASE, 2016, : 312 - 320
  • [29] Experience with ebrantil used in patients with resistant arterial hypertension in chronic kidney disease
    Semenova, R. I.
    Musina, N. S.
    TERAPEVTICHESKII ARKHIV, 2012, 84 (08) : 72 - 74
  • [30] UNCONTROLLED BLOOD PRESSURE AND RESISTANT HYPERTENSION IN ELDERLY CHRONIC KIDNEY DISEASE PATIENTS
    Samal, Lipika
    Wu, Edward
    Aaron, Skye
    McMahon, Gearoid
    Bates, David W.
    Waikar, Sushrut
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (SUPPL 1) : S309 - S310